Ardent Health, Inc. (ARDT) Raises 2026 Adjusted EBITDA Guidance to $500–535M

Ardent Health (ARDT) raised its 2026 adjusted EBITDA guidance to $500–535M from $485–535M, while maintaining revenue guidance at $6,400–6,700M. The board also approved a $25M increase to the share repurchase program. The update follows the company's third-quarter results, but specific quarterly figures were not provided.

Original reporting
Published Nov 4, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ardent Health, Inc. (ARDT) Raises 2026 Adjusted EBITDA Guidance to $500–535M — source image
Decision brief

The 30-second read

$ARDTBullishHigh
01

Why it matters

The raised EBITDA range and larger buyback program provide a fresh positive catalyst for the stock.

02

Market read

Guidance upgrades typically move the stock higher; traders may adjust positions accordingly.

03

What to watch

Potential headwinds from payer negotiations or regulatory changes not discussed.

Relevance 7/10Novelty 8/10Timing: immediate reaction today

Background

Ardent Health (ticker ARDT) issued a press release updating its 2026 financial outlook.

Company-level read

Ticker impact

$ARDTBullishMedium confidence
Context

Ardent Health raised its 2026 adjusted EBITDA guidance to $500‑535M and increased its share repurchase program by $25M.

Expected impact

likely upside as investors price in higher EBITDA and increased buyback support.

Evidence & confidence

The new guidance is material and the first report, providing fresh positive catalyst.

Market effects

May lift sentiment for the broader healthcare services sector.

US healthcare stocks could see modest gains.

Limited to US markets; no global ripple.

Counterpoint

If the guidance increase is already priced in, the stock could face short‑term profit taking.

Key entities

  • Ardent Health, Inc.

    US‑listed healthcare services provider.

Related articles

$ARDTMed

BofA raises Ardent Health stock price target on acquisition upside

BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.

$ARDTMed

What Ardent Health (ARDT) Said on Its Q3 Earnings Call

Ardent Health (ARDT) reported Q3 earnings, highlighting a 9% increase in urgent care visits and a 400 basis point decline in physician referral leakage. Labor costs fell 4.3% YoY, and the company plans to sell a Kansas hospital for 11x EBITDA. Ardent generated $122M in Q3 operating cash flow and lowered its 2026 capital expenditure guidance. The company remains 85% contracted for 2027 and 75% for 2028, with negotiations described as contentious.

$ARDTHighAI 8/10

Ardent Health (ARDT) Q3 2026 Earnings Call Transcript

Ardent Health (ARDT) reported Q3 2026 adjusted EBITDA of $138M, up 1.5% from prior guidance. Revenue was $1.62B, with adjusted admissions up 2.9%. The company plans to divest a Kansas hospital at 11x EBITDA, enhancing margins by 40bps. Ardent's IMPACT program aims for $70M in savings this year, and it raised its EBITDA guidance midpoint by 1.5%.